CN118028093A - Detection device for myocardial infarction marker - Google Patents
Detection device for myocardial infarction marker Download PDFInfo
- Publication number
- CN118028093A CN118028093A CN202410281272.7A CN202410281272A CN118028093A CN 118028093 A CN118028093 A CN 118028093A CN 202410281272 A CN202410281272 A CN 202410281272A CN 118028093 A CN118028093 A CN 118028093A
- Authority
- CN
- China
- Prior art keywords
- detection
- myocardial infarction
- area
- heating device
- result observation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 157
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 41
- 239000003550 marker Substances 0.000 title claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 57
- 238000005070 sampling Methods 0.000 claims abstract description 29
- 238000010241 blood sampling Methods 0.000 claims abstract description 20
- 239000002184 metal Substances 0.000 claims description 21
- 229910052751 metal Inorganic materials 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 229920000742 Cotton Polymers 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000012139 lysis buffer Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 abstract description 38
- 239000002679 microRNA Substances 0.000 abstract description 27
- 238000011901 isothermal amplification Methods 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 8
- 108091033409 CRISPR Proteins 0.000 abstract description 7
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000000605 extraction Methods 0.000 abstract description 3
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 16
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 108700004991 Cas12a Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 108091023685 miR-133 stem-loop Proteins 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 238000009739 binding Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150059443 cas12a gene Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a detection device of myocardial infarction markers, comprising: a device body, an outer cover; the outer cover is detachably covered outside the device main body; the device body includes: the drawer comprises a heating device, a detection result observation area and a drawer; the heating device and the detection result observing area are positioned at the upper part of the device main body; the drawer is positioned at the lower part of the device main body and can be pulled out and pushed in from the device main body; the heating device is in flow connection with the detection result observation area; the detection result observation area comprises a detection area and a result observation area, and the result observation area is detachably connected with the detection area and is in signal connection with the detection area; the drawer is provided with a detection card, a sampling tube and a blood sampling tool. The invention integrates the extraction, heating and detection, is convenient and quick, accurately detects myocardial infarction diseases, realizes zero breakthrough of the myocardial infarction detection device, reduces the cost and is convenient and quick to operate; miRNA is used as a myocardial infarction detection marker, and the isothermal amplification and the reverse cutting function of the CRISPR technology are combined, so that the myocardial infarction detection efficiency and accuracy are effectively improved.
Description
Technical Field
The invention relates to the technical field of myocardial infarction detection devices, in particular to an innovative device for diagnosing myocardial infarction.
Background
In recent years, treatment of acute myocardial infarction has received increasing attention. After suffering from acute myocardial infarction, cardiomyocytes respond to ischemic extracellular stimuli, and can then activate various pathological gene programs and reprogram gene expression.
Studies have shown that abnormal expression of mirnas can lead to overgrowth or excessive differentiation of cells, mirnas can serve as biomarkers in myocardial infarction diseases. Some mirnas, such as miRNA-133 and miRNA-499, play a key role in regulating overall cardiac function. Plasma levels of miRNA-133 were reported to increase sharply after appearance of AMI symptoms and return to normal levels within 15 hours. Since these specific mirnas have proven to be critical in regulating important cardiomyocyte activity following an acute myocardial infarction outbreak, abnormally high levels of mirnas in the circulating blood are generally considered markers of acute myocardial infarction, especially in the early stages.
Inhibition of miR-133 on myocardial apoptosis, low expression of miR-133 in human and mouse cardiac hypertrophy models, and high expression of miR-133 in vitro can inhibit cardiac hypertrophy. Expression of miR-133 in an animal model of myocardial infarction and its effect on cardiac function. miRNA-133 is specifically expressed in the heart and plays an important regulatory role in heart development, myocardial apoptosis and myocardial remodeling. miR-133 has anti-apoptotic effect. The miRNA-22 and GRACE scores have strong identification capability on MACE occurrence, the sensitivity is 100.00%, and the specificity is 79.40%. miRNA-22 is more sensitive and specific to diagnosis of AMI, and is suggested to be used as a potential biomarker for clinical diagnosis of AMI.
At present, a kit or a test strip is mainly used for detecting myocardial infarction in the market, wherein the kit or the test strip for detecting myocardial infarction adopts a detection method of cardiac troponin I (cTnI), which is a structural protein in myocardial cells, and when the myocardial cells are damaged, the cTnI is released into blood, so that cardiovascular diseases are measured by the concentration of the cTnI and prognosis evaluation is carried out.
The detection method of the cardiac troponin I (cTnI) mainly comprises the following steps:
1. Chemiluminescence method: the method adopts the antigen-antibody reaction principle, marks a substance with chemiluminescence characteristics on a cTnI antibody, and determines the concentration of the cTnI by detecting the luminous intensity after the substance is specifically combined with the corresponding cTnI antigen in a sample. The chemiluminescence method has the advantages of higher sensitivity and specificity and high automation degree. However, the instrumentation of chemiluminescence is expensive and requires specialized personnel to operate.
2. Immunoprecipitation method: the concentration of cTnI is determined by adding cTnI antibodies to a sample, specifically binding with cTnI antigens in the sample, forming an immune complex, separating the immune complex from other substances by centrifugation, and finally determining the amount of the immune complex. The immunoprecipitation method is simple to operate, low in cost and suitable for batch detection. But the sensitivity and specificity of immunoprecipitation are relatively low.
3. Biosensor method: the biological recognition element is analyzed in combination with the transducer. In cTnI detection, biological recognition elements such as cTnI antibodies or nucleic acid probes are fixed on the surface of a transducer, and when the transducer contacts cTnI in a sample, a specific binding reaction occurs, and a chemical signal is converted into an electrical signal by the transducer, so that the concentration of cTnI is measured. The biosensor method has the advantages of high sensitivity, high specificity, low cost and the like, but has higher requirements on the manufacturing and detection environment of the transducer.
Moreover, traditional miRNA detection still faces a significant challenge:
(1) The content of miRNA is low, and false negative results are easy to occur due to insufficient sensitivity of the detection method, so that a high-sensitivity method needs to be developed for detecting the low-abundance miRNA:
(2) The operation is complex, and precise detection instruments and professional detection personnel are needed, so that a method which is easy to operate and can be used for on-site detection needs to be developed;
(3) Expensive and low cost detection methods need to be developed.
Disclosure of Invention
In view of this, the invention aims to innovate the myocardial infarction detection method, integrate the steps of extraction, heating and detection, realize zero breakthrough of the myocardial infarction detection device, develop miRNA detection device related to myocardial infarction, reduce cost and improve operation convenience; miRNA is used as a marker for myocardial infarction detection, isothermal amplification and reverse cleavage function of CRISPR technology are combined, and myocardial infarction detection efficiency and accuracy are improved.
The invention provides a detection device of myocardial infarction markers, comprising:
A device body, an outer cover; the outer cover is detachably covered outside the device main body;
Wherein the device body includes: the drawer comprises a heating device, a detection result observation area and a drawer; the heating device and the detection result observing area are positioned at the upper part of the device main body; the drawer is positioned at the lower part of the device main body and can be pulled out and pushed in from the device main body; the heating device is in flow connection with the detection result observation area;
The detection result observation area includes: the device comprises a detection area and a result observation area, wherein the result observation area is detachably connected with the detection area and is in signal connection with the detection area;
The drawer is internally provided with a detection card, a sampling tube and a blood sampling tool, wherein the detection card is positioned below the detection area, and the sampling tube and the blood sampling tool are positioned below the heating device.
Further, the heating device is a metal bath heating device, the metal bath heating device includes: a plurality of heating ports, temperature adjusting buttons, time adjusting buttons and metal bath switches; the heating port is positioned on the upper surface of the metal bath heating device; the temperature adjusting button and the time adjusting button are positioned on one side of the metal bath heating device facing the inspector, and the metal bath switch is positioned on one side of the metal bath heating device facing away from the inspector.
Further, the detection area is provided with an ultraviolet lamp panel and an ultraviolet lamp panel switch, the ultraviolet lamp panel is positioned on one side of the detection area facing the detector, and the ultraviolet lamp panel switch is positioned on one side of the detection area not facing the detector.
Further, a detection clamping groove is formed in the joint of the detection area and the result observation area, and the detection clamping groove is located above the ultraviolet lamp panel; the detection bayonet is arranged at the joint of the result observation area and the detection area, and the detection clamping groove is in clamping connection with the detection bayonet.
Further, the result observation area includes: the baffle is positioned on the upper surface of the result observation area, and the observation window is arranged in the middle of the baffle. The baffle protects the user from the ultraviolet lamp.
Further, the sampling tube comprises a lysis buffer and a buffer containing protein, wherein the lysis buffer and the buffer containing protein are separated by an insoluble membrane.
Further, the blood collection tool includes: blood taking needle, iodophor, common cotton swab and 75% alcohol wet towel.
Further, the detection card includes: a sample inlet and a protective cover; the sample adding port is arranged in the middle of the detection card, and the protective cover is detachably connected to the edge of the detection card.
Further, the number of the heating ports is 12 which are uniformly arranged in an array.
The process steps of a preferred embodiment of the invention are as follows:
Extracting: the sampling tube, 75% alcohol wet towel, blood taking needle and cotton swab are taken out from the drawer. The blood sampling part is pierced by a blood sampling needle, and is dripped into a sampling tube, the sampling tube contains a lysis buffer solution and a buffer solution containing Cas12a protein, the sampling tube is extruded, blood is contacted with a reaction solution, and miRNA to be detected is extracted.
Heating: the well mixed sampling tube is placed into a heating port of a heating device, heated for 10 minutes at 37 ℃ and fully reacted.
And (3) detection: taking out the detection card from the drawer, dripping the heated sampling tube into the sample feeding port of the detection card, inserting the detection card into the detection card slot, opening the ultraviolet lamp panel switch on the right side of the device, and observing the result.
The using steps are as follows:
1. Opening the outer cover of the device, opening the drawer, taking out the 75% alcohol wet towel and wiping and sterilizing the hands. And taking out the detection card and placing the detection card on a table top.
2. And taking out one iodophor cotton swab, breaking off the iodophor cotton swab to flow onto the cotton swab, and wiping the blood sampling part.
3. The blood sampling part is pierced by a blood taking needle, then blood is dripped into a sampling tube, and a common cotton swab is taken out to lightly press the blood sampling part.
4. The sample tube was squeezed on both sides to break the insoluble membrane in order to mix the solution in the upper half of the tube with the lower half (lysis buffer and buffer containing Cas12a protein).
5. And placing the mixed sampling tube into a heating port of a heating device, heating for 10 minutes at the temperature of 37 ℃, taking out, and dripping the mixed sampling tube into a sample adding port of a detection card.
6. And inserting the detection card into the detection card slot, turning on the right ultraviolet lamp, waiting for a moment, and observing the result.
The innovative myocardial infarction marker detection device has the following action principle: colloidal gold is used to modify gene fragments with different hairpin structures and target different gene fragments to different miRNAs. After binding to miRNA, the HCR isothermal amplification reaction is triggered. Meanwhile, by utilizing the reverse cutting function of the CRISPR technology, fluorescent signals are released, and miRNA detection is completed. The device combines the functions of a colloidal gold technology, an HCR isothermal amplification technology, CRISPR reverse cutting and the like, establishes a specific detection method of miRNA, and predicts whether a patient suffers from myocardial infarction according to detection results.
Compared with the prior art, the invention has the beneficial effects that:
The detection device for the myocardial infarction markers integrates the extraction, heating and detection, is convenient and quick, accurately detects myocardial infarction diseases, realizes zero breakthrough of the myocardial infarction detection device, reduces the cost and is convenient and quick to operate; the miRNA is used as a marker for myocardial infarction detection, the isothermal amplification and the reverse cutting function of the CRISPR technology are combined, expensive or complex instruments are not needed in the detection process, no special requirements are required for operators, the detection result can be realized through simple operation, the detection time is short, whether the myocardial infarction disease is about to be caused or not can be detected in advance by adopting miRNA in blood before the myocardial infarction, the physical health condition is conveniently predicted in advance, and measures are taken to treat or inject vaccine in advance to reduce the risk of the disease; the method has the advantages that the method can be used for predicting and primarily screening myocardial infarction diseases in advance in high efficiency and large scale in underdeveloped areas with poor medical care, so that patients with myocardial infarction disease screening requirements can quickly obtain results, whether acute myocardial infarction is likely to occur or not is determined in advance, and the efficiency and accuracy of myocardial infarction detection are effectively improved.
Drawings
Various other advantages and benefits will become apparent to those of ordinary skill in the art upon reading the following detailed description of the preferred embodiments. The drawings are only for purposes of illustrating the preferred embodiments and are not to be construed as limiting the invention.
In the drawings:
FIGS. 1-4 are schematic diagrams showing the structural components of the detection device for myocardial infarction markers according to the present invention;
FIG. 5 is a graph showing the specific results of an isothermal amplification reaction initiated by miRNA according to the present invention;
FIG. 6 is a schematic diagram of a detection result of a device according to an embodiment of the present invention;
FIG. 7 is an electrophoretogram of the results of miRNA priming and HCR isothermal amplification reactions according to embodiments of the present invention;
Fig. 8 is a graph showing the judgment of the detection result of miRNA according to the application example of the present invention.
The labels in the figures are:
1. The device comprises an outer cover, 2, a baffle, 3, a detection bayonet, 4, a detection clamping groove, 5, an ultraviolet lamp panel, 6, a drawer, 7, a metal bath heating device, 8, a heating port, 9, a temperature adjusting button, 10, a time adjusting button, 11, an observation window, 12, an ultraviolet lamp panel switch, 13, a detection card, 14, a sample adding port, 15, a protective cover, 16, a blood taking needle, 17, iodophor and a common cotton swab, 18, a sampling tube, 19, 75% alcohol wet tissues, 20 and a metal bath switch.
Detailed Description
Reference will now be made in detail to exemplary embodiments, examples of which are illustrated in the accompanying drawings. When the following description refers to the accompanying drawings, the same numbers in different drawings refer to the same or similar elements, unless otherwise indicated. The implementations described in the following exemplary examples are not representative of all implementations consistent with the present disclosure. Rather, they are merely examples of systems and products consistent with some aspects of the present disclosure as detailed in the appended claims.
The terminology used in the present disclosure is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. As used in this disclosure and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It should also be understood that the term "and/or" as used herein refers to and encompasses any or all possible combinations of one or more of the associated listed items.
It should be understood that although the terms first, second, third, etc. may be used in this disclosure to describe various information, these information should not be limited to these terms. These terms are only used to distinguish one type of information from another. For example, first information may also be referred to as second information, and similarly, second information may also be referred to as first information, without departing from the scope of the present disclosure. The word "if" as used herein may be interpreted as "at … …" or "at … …" or "in response to a determination" depending on the context.
Embodiments of the present invention will be described in further detail below with reference to the accompanying drawings.
An embodiment of the present invention provides a device for detecting a myocardial infarction marker, as shown in fig. 1 to 4, including:
A device body, an outer cover (1); the outer cover (1) is detachably covered outside the device main body;
Wherein the device body includes: a heating device (7), a detection result observation area and a drawer (6); the heating device (7) and the detection result observing area are positioned at the upper part of the device main body; the drawer (6) is positioned at the lower part of the device main body and can be pulled out and pushed in from the device main body; the heating device (7) is in flow connection with the detection result observation area;
The detection result observation area includes: the device comprises a detection area and a result observation area, wherein the result observation area is detachably connected with the detection area and is in signal connection with the detection area;
The drawer is internally provided with a detection card (13), a sampling tube (18) and a blood sampling tool, the detection card (13) is positioned below the detection area, and the sampling tube (18) and the blood sampling tool are positioned below the heating device (7).
The heating device (7) is a metal bath heating device comprising: a plurality of heating ports (8), a temperature adjusting button (9), a time adjusting button (10) and a metal bath switch (20); the heating port (8) is positioned on the upper surface of the metal bath heating device; the temperature adjusting button (9) and the time adjusting button (10) are positioned on one side of the metal bath heating device facing the detector, and the metal bath switch (20) is positioned on one side of the metal bath heating device facing away from the detector.
In this embodiment, the number of the heating ports (8) is 12, which are uniformly arranged in an array.
The detection area is provided with an ultraviolet lamp panel (5) and an ultraviolet lamp panel switch (12), the ultraviolet lamp panel (5) is positioned on one side of the detection area facing the detector, and the ultraviolet lamp panel switch (12) is positioned on one side of the detection area not facing the detector.
A detection clamping groove (4) is formed in the joint of the detection area and the result observation area, and the detection clamping groove (4) is positioned above the ultraviolet lamp panel (5); the detection bayonet (3) is arranged at the joint of the result observation area and the detection area, and the detection clamping groove (4) is in clamping connection with the detection bayonet (3).
The result observation area includes: baffle (2), observation window (11), baffle (2) are located the upper surface of result observation district, observation window (11) set up in the middle of baffle (2). The baffle (2) protects the user from the ultraviolet lamp.
The sampling tube (18) comprises a lysis buffer, a protein-containing buffer, the lysis buffer, the protein-containing buffer being separated by an insoluble membrane.
The blood collection tool includes: a blood taking needle (16), an iodophor, a common cotton swab (17) and a 75% alcohol wet tissue (19).
The test card (13) comprises: a sample inlet (14), a protective cover (15); the sample adding port (14) is arranged in the middle of the detection card (13), and the protective cover (15) is detachably connected to the edge of the detection card (13).
The operation steps of the embodiment of the invention are as follows:
Extracting: the sampling tube (18), the 75% alcohol wet tissue (19), the blood taking needle (16) and the cotton swab (17) are taken out from the drawer (6). The blood sampling needle (16) is used for puncturing the blood sampling part, the blood sampling part is dripped into the sampling tube (18), the sampling tube (18) contains a lysis buffer solution and a buffer solution containing Cas12a protein, the sampling tube (18) is extruded, blood is contacted with the reaction solution, and miRNA to be detected is extracted.
Heating: the well-mixed sampling tube (18) is placed into a heating port (8) of a heating device (7), and is heated for 10 minutes at 37 ℃ to fully react.
And (3) detection: taking out the detection card (13) from the drawer (6), dripping the heated sampling tube (18) to the sample feeding port (14) of the detection card (13), inserting the detection card (13) into the detection card slot (4), and turning on the ultraviolet lamp panel switch (12) on the right side of the device to observe the result.
The using steps are as follows:
1. The outer cover (1) of the device is opened, the drawer (6) is opened, and the hand is wiped and disinfected by taking out the 75% alcohol wet tissue (19). And taking out the detection card (13) and placing the detection card on a table top horizontally.
2. And taking out an iodophor cotton swab (17), breaking off the iodophor cotton swab to flow onto the cotton swab, and wiping the blood sampling part.
3. The blood sampling needle (16) is used for puncturing the blood sampling part, then blood is dripped into the sampling tube (18), and a common cotton swab (17) is taken out to lightly press the blood sampling part.
4. The sample tube (18) is squeezed on both sides to break the insoluble membrane so that the solution in the upper half of the tube is mixed with the solution in the lower half (lysis buffer and buffer containing Cas12a protein).
5. The mixed sampling tube (18) is placed into a heating port (8) of a heating device (7), the temperature is set to 37 ℃, the heating is carried out for 10 minutes, and the sampling tube is taken out and dripped into a sample adding port (14) of a detection card (13).
6. The detection card (13) is inserted into the detection card slot (4), the right ultraviolet lamp (12) is turned on, and the result is observed after waiting for a moment.
Fig. 6 shows the detection result of the device according to the embodiment of the present invention.
See fig. 7 for an electrophoresis chart of the results of the isothermal amplification reaction of miRNA-initiated HCR according to the present invention, lane 1: h1 (1. Mu.M); lane 2: h2 (1. Mu.M); lane 3:1 mu M H1+1 mu M H2; lane 4:1 mu M H1+1 mu M H2+50nM miR; lane 5:1 mu M H1+1 mu M H2+100nM miR; lane 6:1 mu M H1+1 mu M H2+200nM miR; lane 7:1 mu M H1+1 mu M H2+500nM miR-; lane 8:1 mu M H1+1 mu M H2+1000nM miR.
Only H1H 2 can not trigger amplification reaction, but can be triggered by adding miRNA, the shape of amplified bands triggered by miRNA with different concentrations is similar, the result of trapezoidal bands is shown, and the higher the miRNA concentration is, the faster the reaction speed is.
As can be seen from fig. 5, the embodiment of the present invention has a high specificity. Different mirnas can target different hairpin structures, so that an amplification reaction is triggered, and obvious differences exist between the color change and blank and other types of mirnas, and good method specificity is shown.
Application example
The specific technical route of miRNA detection comprises the following steps: designing gene fragments with different hairpin structures, targeting different miRNAs by the different gene fragments, combining the gene fragments with the miRNAs to trigger HCR isothermal amplification reaction, simultaneously releasing fluorescent signals by utilizing the reverse cleavage function of the CRISPR technology, and finally performing color reaction on a lateral flow chromatography test strip to finish miRNA detection.
The principle of the test strip is as follows: the lateral flow chromatography Test Strip (LETs) has the advantages of simple operation, rapid detection, low cost, convenient carrying, no need of auxiliary large-scale instruments and the like, and has been widely applied to the fields of analysis of small molecules, proteins, cancer cells, nucleic acids and the like. The nucleic acid amplification product based on HCR isothermal amplification is combined with LETs, and the lateral flow chromatography test strip is used for: the lateral chromatography test strip is adopted, and is provided with two strips, a lower quality control line and an upper detection line. And (3) coating avidin (SA) on the quality control line, coating goat anti-mouse secondary antibody on the detection line, and labeling anti-FAM monoclonal antibody on the colloidal gold. The complete reporter (Biotin and FAM are respectively marked at the two ends) can lead the colloidal gold to be completely captured at the quality control line, and when the reporter (reporter) is cut off by the Cas enzyme, the colloidal gold combined with the cut-off segment can not be captured by the quality control line to form a detection line. Whether the Cas enzyme is activated or not is judged through the existence of the detection line, so that the sensitivity is effectively improved, the operation is simple, the price is low, the design is easy, and more possibility is provided for LETs to be used for detecting low-abundance nucleic acid. In certain cases, single step signal amplification has not been satisfactory due to the extremely low target content, and LETs may be combined with a multi-step tandem HCR amplification nucleic acid signal amplification strategy in order to further increase the sensitivity and accuracy of les.
The specific use flow is as follows:
CRISPR/Cas12amiRNA detection (two-step method):
cas12a forms a functional complex with crRNA, "coasting" on the amplified product of DNA, and after successful pairing Cas12a is specifically activated, trans-cleaving the surrounding reporter. The characteristic can be used in the field of molecular diagnosis to realize the detection of the target to be detected. The detection method combines the isothermal amplification technology (37 ℃) and the characteristics of Cas12a together, so as to realize the ultra-sensitive and rapid detection of miRNA.
Reagent composition (as shown in table 1):
TABLE 1
Operation step 1:
1. After thawing on ice, the reagents were mixed.
2. Isothermal amplification reactions, for example, a 20. Mu.l reaction system was prepared (note: on ice operation), see Table 2:
TABLE 2
| 1 | PH7.2 buffer (2X) | 10μl |
| 2 | miRNA(20μM) | 0.5μl |
| 3 | H1(1μM) | 0.5μl |
| 4 | H2(1μM) | 0.5μl |
| 5 | Nuclease-freeH2O | Make up to a total volume of 20. Mu.l |
3. Flicking for several times, mixing, slightly centrifuging (avoiding vortex violent vibration), repeating for 3 times
Incubation at 4.37℃for 30 min
5. Specific target sequences were detected using Cas12a, the thermostats were opened in advance and the reaction temperature was set to 37 ℃.
Operating step 2:
20 μl of the reaction system was prepared (note: on ice operation), see Table 3:
TABLE 3 Table 3
* And (3) adding the isothermal amplification product obtained in the step (2), wherein the template loading amount recommended by the template with high concentration is 2 mu L, and x is less than or equal to 5 mu L.
6. Flicking for several times, mixing, slightly centrifuging (avoiding vortex violent vibration), repeating for 3 times
7. The reaction tube was placed at 37℃for 45min.
8. 10 Mu L of the nucleic acid amplification product is taken, diluted 5 times by 40 mu L of ddH2O in a centrifuge tube and evenly mixed;
9. The diluted reaction products are all dripped on a nucleic acid detection test strip (or the test strip is inserted into the diluted products, and the detection result of the interpretation zone is recorded within 5 minutes).
10. After recording the detection result, the test strip is discarded at a safety place after being sealed.
Result judgment (see fig. 8):
negative: the T line is not developed, and is judged as negative, which indicates that the reporter (reporter) is not cut by the Cas enzyme, and the Cas enzyme is not activated;
Positive: the T line is macroscopic, judging positive, indicating that there is a nucleic acid probe cleaved by Cas enzyme, and Cas enzyme is activated.
Thus far, the technical solution of the present invention has been described in connection with the preferred embodiments shown in the drawings, but it is easily understood by those skilled in the art that the scope of protection of the present invention is not limited to these specific embodiments. Equivalent modifications and substitutions for related technical features may be made by those skilled in the art without departing from the principles of the present invention, and such modifications and substitutions will be within the scope of the present invention.
The foregoing description is only of the preferred embodiments of the invention and is not intended to limit the invention; various modifications and variations of the present invention will be apparent to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. A device for detecting a marker of myocardial infarction, comprising: a device body, an outer cover (1); the outer cover (1) is detachably covered outside the device main body;
Wherein the device body includes: a heating device (7), a detection result observation area and a drawer (6); the heating device (7) and the detection result observing area are positioned at the upper part of the device main body; the drawer (6) is positioned at the lower part of the device main body and can be pulled out and pushed in from the device main body; the heating device (7) is in flow connection with the detection result observation area;
The detection result observation area includes: the device comprises a detection area and a result observation area, wherein the result observation area is detachably connected with the detection area and is in signal connection with the detection area;
The drawer is internally provided with a detection card (13), a sampling tube (18) and a blood sampling tool, the detection card (13) is positioned below the detection area, and the sampling tube (18) and the blood sampling tool are positioned below the heating device (7).
2. The device for detecting myocardial infarction markers as set forth in claim 1, characterized in that the heating device (7) is a metal bath heating device comprising: a plurality of heating ports (8), a temperature adjusting button (9), a time adjusting button (10) and a metal bath switch (20); the heating port (8) is positioned on the upper surface of the metal bath heating device; the temperature adjusting button (9) and the time adjusting button (10) are positioned on one side of the metal bath heating device facing the detector, and the metal bath switch (20) is positioned on one side of the metal bath heating device facing away from the detector.
3. The myocardial infarction marker detection apparatus as set forth in claim 2, wherein the detection area is provided with an ultraviolet lamp panel (5) and an ultraviolet lamp panel switch (12), the ultraviolet lamp panel (5) is located at a side of the detection area facing the detector, and the ultraviolet lamp panel switch (12) is located at a side of the detection area not facing the detector.
4. The myocardial infarction marker detection device as set forth in claim 3, wherein a detection slot (4) is provided at the junction of the detection area and the result observation area, the detection slot (4) being located above the ultraviolet lamp panel (5); the detection bayonet (3) is arranged at the joint of the result observation area and the detection area, and the detection clamping groove (4) is in clamping connection with the detection bayonet (3).
5. The device for detecting myocardial infarction markers as set forth in claim 4, wherein the result observation region includes: baffle (2), observation window (11), baffle (2) are located the upper surface of result observation district, observation window (11) set up in the middle of baffle (2).
6. The device for detecting myocardial infarction markers as set forth in claim 1, characterized in that the sampling tube (18) comprises a lysis buffer, a protein-containing buffer, separated by an insoluble membrane.
7. The device for detecting a marker of myocardial infarction as set forth in claim 1, wherein the blood sampling tool includes: a blood taking needle (16), an iodophor, a common cotton swab (17) and a 75% alcohol wet tissue (19).
8. The device for detecting myocardial infarction markers as set forth in claim 7, wherein the detection card (13) includes: a sample inlet (14), a protective cover (15); the sample adding port (14) is arranged in the middle of the detection card (13), and the protective cover (15) is detachably connected to the edge of the detection card (13).
9. The myocardial infarction marker detection apparatus as set forth in claim 2, wherein the number of the heating ports (8) is 12 arranged in a uniform array.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410281272.7A CN118028093A (en) | 2024-03-12 | 2024-03-12 | Detection device for myocardial infarction marker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410281272.7A CN118028093A (en) | 2024-03-12 | 2024-03-12 | Detection device for myocardial infarction marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118028093A true CN118028093A (en) | 2024-05-14 |
Family
ID=90987644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410281272.7A Pending CN118028093A (en) | 2024-03-12 | 2024-03-12 | Detection device for myocardial infarction marker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118028093A (en) |
-
2024
- 2024-03-12 CN CN202410281272.7A patent/CN118028093A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1190231A4 (en) | System for electrochemical quantitative analysis of analytes within a solid phase | |
| ATE290210T1 (en) | USE OF ANTIBODIES TO EMBRYONAL HEMOGLOBIN FOR IDENTIFYING FETAL CELLS | |
| US20080268464A1 (en) | Process And Device For Determining The Activity Of Enzymes In Liquids, Or The Concentration And/Or Activity Of Inhibitors In Liquids | |
| US10935495B2 (en) | Detection and analysis method for urine-modified nucleoside based on surface-enhanced resonance Raman spectroscopy | |
| Ferrara et al. | Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics | |
| CN109762899A (en) | A kind of kit carrying out the probability that Noninvasive testing suffers from bladder cancer using urine excretion body | |
| RU2014122607A (en) | METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY TO IN-HOSPITAL INFECTION AND FORMING A FORECAST OF SEPTIC SYNDROME DEVELOPMENT | |
| CN108048589A (en) | The Real-time PCR specific primers and probe and detection kit and detection method of ox two-pressure humidity generator | |
| FI20196004A1 (en) | Device and method for detecting of brain injury in a subject | |
| RU2748540C1 (en) | Method for detecting sars-cov-2 virus by mass spectrometry | |
| CN109355406A (en) | A kind of kit of the detection mycobacterium tuberculosis based on blood free nucleic acid | |
| CN107641649B (en) | Primer pair, kit and method for detecting stability of NR27 locus of microsatellite | |
| Zhang et al. | A highly sensitive and versatile fluorescent biosensor for pathogen nucleic acid detection based on toehold-mediated strand displacement initiated primer exchange reaction | |
| CA2960859A1 (en) | Hybrid multi-step nucleic acid amplification | |
| CN118028093A (en) | Detection device for myocardial infarction marker | |
| CN108588218B (en) | Serum miRNA combined minimally invasive detection kit | |
| CN109825585A (en) | A kind of biomarker of nasopharyngeal carcinoma diagnosis and/or prognosis evaluation | |
| Hamada et al. | Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas | |
| JP2004053363A (en) | Electrochemical test piece having multiple reaction chamber and method for using the same | |
| CN108802354B (en) | Urine detection method | |
| EP3521443A1 (en) | Saliva test for early cancer diagnosis | |
| CN110004227A (en) | A kind of biomarker of nasopharyngeal carcinoma diagnosis and/or prognosis evaluation | |
| US11497817B2 (en) | Senile dementia treatment formulation and application thereof | |
| WO2001086288A2 (en) | Early diagnosis of bladder tumor in urine samples | |
| Koch et al. | Highly multiplexed detection of microRNAs, proteins and small molecules using barcoded molecular probes and nanopore sequencing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |